Pharma major Lupin Ltd. announced Monday that it has divested its U.S. Commercial Women\'s Health Specialty Business to Evofem Biosciences, Inc. (EVFM), a U.S. biopharmaceutical company focused exclusively on Women\'s Health.
Lupin\'s U.S. Commercial Women\'s Health Specialty Business is primarily focused on commercializing SOLOSEC (secnidazole) 2g oral granules.
This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.